The week in pharma: action, reaction and insight – week to May 12, 2023

14 May 2023

By Barbara Obstoj-Cardwell. Editor

US biopharma firm Insmed held a meeting with analysts last Monday, when it unveiled a new research platform in the area of Duchenne muscular dystrophy and other diseases. Two M&A deals featured last week, first with US biotech major Gilead Sciences revealing the acquisition of XinThera, which will expand its early-stage oncology and inflammatory diseases portfolio. Also, Swedish Orphan Biovitrum (Sobi) announced it is acquiring US biotech CTI BioPharma, along with its hematology drug Vonjo, in order to expand its position in this rare disease sector. Meantime, US drugmaker Reata Pharmaceuticals reported a setback for its Friedreich’s ataxia drug Skyclarys with a New Drug Application (NDA) submitted to the Food and Drug Administration (FDA) to increase the drug substance specification for a process impurity observed above the current specification during process validation.

Insmed R&D day highlights next wave of differentiated programs in DMD and beyond

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK